Cingulate Correlations
| CING Stock | USD 6.82 0.88 11.43% |
The current 90-days correlation between Cingulate and Lixte Biotechnology Holdings is 0.03 (i.e., Significant diversification). The correlation of Cingulate is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Cingulate Correlation With Market
Very poor diversification
The correlation between Cingulate and DJI is 0.81 (i.e., Very poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Cingulate and DJI in the same portfolio, assuming nothing else is changed.
Cingulate | Build AI portfolio with Cingulate Stock |
Moving together with Cingulate Stock
| 0.63 | DSGN | Design Therapeutics | PairCorr |
| 0.66 | ENGN | enGene Holdings Common | PairCorr |
| 0.63 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.71 | MRKR | Marker Therapeutics | PairCorr |
| 0.62 | AVE | Avecho Biotechnology | PairCorr |
| 0.75 | ANNX | Annexon | PairCorr |
| 0.74 | SLDB | Solid Biosciences LLC | PairCorr |
| 0.73 | AVCR | Avricore Health | PairCorr |
| 0.64 | BOLT | Bolt Biotherapeutics | PairCorr |
| 0.81 | TNGX | Tango Therapeutics | PairCorr |
| 0.61 | CADL | Candel Therapeutics | PairCorr |
Moving against Cingulate Stock
| 0.91 | ABP | Abpro Holdings | PairCorr |
| 0.87 | KURA | Kura Oncology | PairCorr |
| 0.82 | DWTX | Dogwood Therapeutics | PairCorr |
| 0.8 | GNLX | Genelux Common | PairCorr |
| 0.77 | EDIT | Editas Medicine | PairCorr |
| 0.77 | LYRA | Lyra Therapeutics | PairCorr |
| 0.67 | IMRN | Immuron Ltd ADR | PairCorr |
| 0.59 | QSI | QuantumSi | PairCorr |
| 0.39 | EVGN | Evogene | PairCorr |
| 0.32 | LRMR | Larimar Therapeutics | PairCorr |
| 0.83 | PRQR | ProQR Therapeutics | PairCorr |
| 0.79 | MBIO | Mustang Bio | PairCorr |
| 0.78 | ACXP | Acurx Pharmaceuticals LLC | PairCorr |
| 0.76 | MREO | Mereo BioPharma Group | PairCorr |
| 0.57 | PROK | ProKidney Corp | PairCorr |
Related Correlations Analysis
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Cingulate Stock performing well and Cingulate Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Cingulate's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ALLR | 3.64 | (0.61) | 0.00 | (0.33) | 0.00 | 6.93 | 19.54 | |||
| LEXX | 5.18 | (0.61) | 0.00 | (0.22) | 0.00 | 9.23 | 42.53 | |||
| LIXT | 3.37 | (0.43) | 0.00 | (0.99) | 0.00 | 7.71 | 19.11 | |||
| KAPA | 4.16 | (0.49) | 0.00 | (0.18) | 0.00 | 9.41 | 26.15 | |||
| SYBX | 3.76 | (1.15) | 0.00 | 1.74 | 0.00 | 5.36 | 56.19 | |||
| CASI | 3.59 | (0.53) | 0.00 | (0.53) | 0.00 | 5.10 | 32.11 | |||
| CLSD | 6.75 | (3.10) | 0.00 | (2.66) | 0.00 | 7.96 | 83.67 | |||
| ENTO | 7.46 | (0.01) | 0.00 | 0.10 | 0.00 | 16.86 | 39.61 | |||
| NCNA | 3.40 | (0.81) | 0.00 | (0.33) | 0.00 | 6.53 | 20.76 | |||
| BCTX | 6.74 | (0.68) | 0.00 | (0.42) | 0.00 | 13.96 | 98.43 |
Cingulate Corporate Management
| Craig Esq | Gen VP | Profile | |
| Thomas Dalton | Head Relations | Profile | |
| Bryan Downey | Chief Officer | Profile | |
| Downey Wade | Chief Officer | Profile |